BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 22
• 23
• 24
• 25
• 26
• 27
• 30
• 31

• Press Releases

  Curi Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of New Approach Methods in Neuromuscular Pharmacology

  March 23, 2026

   · 

  3 min read
• Press Releases

  Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

  March 23, 2026

   · 

  2 min read
• Press Releases

  IBA Launches myQAMatriXXAiR to Advance Patient‑Specific QA in Particle Therapy

  March 23, 2026

   · 

  3 min read
• Press Releases

  Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) - March 20, 2026

  March 23, 2026

   · 

  1 min read
• Press Releases

  Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - March 20, 2026

  March 23, 2026

   · 

  1 min read
• Press Releases

  Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026

  March 23, 2026

   · 

  7 min read
• Press Releases

  Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study

  March 23, 2026

   · 

  7 min read
• Press Releases

  Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody

  March 23, 2026

   · 

  6 min read
• Press Releases

  Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026

  March 23, 2026

   · 

  1 min read
• Press Releases

  IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial

  March 23, 2026

   · 

  3 min read